^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Qibeian (iparomlimab/tuvonralimab)

    i
    Other names: PSB205 , PSB-205, PSB 205 , Anti-PD-1/CTLA-4 MabPair, QL1706, PBS-103/PBS-105, QL 1706, QL-1706
    Company:
    Qilu Pharma, Sound Biologics
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    22h
    Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial. (PubMed, EClinicalMedicine)
    Patients received radiotherapy (50.4 Gy/28 in fractions on 5 days per week), concurrent chemotherapy (paclitaxel 135 mg/m2 d1+ cisplatin 25 mg/m2 d1-3, q3w, 2 cycles), and QL1706 (5 mg/kg q3w for up to 1 year [total of 18 cycles]). QL1706 combined with chemoradiotherapy demonstrated potential antitumor activity and manageable toxicity, supporting further investigation. National Natural Science Foundation of China, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Medical Discipline Construction Project, and Tianjin Key Medical Discipline (Specialty) Construction Project.
    P2 data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • FASLG (Fas ligand) • ZFHX4 (Zinc Finger Homeobox 4)
    |
    TMB-H
    |
    cisplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    2d
    Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    A Phase II Clinical Study of Sequential Iparomlimab and Tuvonralimab Combined with Chemotherapy Following Local Radiotherapy in Breast Cancer Patients with Poor Response to Neoadjuvant Chemotherapy (ChiCTR2600117206)
    P=N/A, N=30, Not yet recruiting, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    carboplatin • albumin-bound paclitaxel • epirubicin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    Exploratory Study of Transarterial Chemoembolization (TACE) Combined with Eparlitozoviril Antibody and Lenvatinib for Intermediate-to-Advanced Hepatocellular Carcinoma (ChiCTR2600117109)
    P=N/A, N=30, Recruiting, The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University
    New trial
    |
    Lenvima (lenvatinib) • epirubicin • Qibeian (iparomlimab/tuvonralimab)
    3d
    Study on the efficacy and safety of QL1706 combined with Senaparib in neoadjuvant therapy for ovarian Cancer: A prospective, single-arm clinical study (ChiCTR2600116175)
    P=N/A, N=20, Not yet recruiting, The Fourth Hospital of Hebei Medical University; Fourth Hospital of Hebei Medical University
    New trial
    |
    Paishuning (senaparib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    A single-center, single-arm clinical study on the efficacy and safety of Iparomlimab and Tuvonralimab combined with chemotherapy as neoadjuvant therapy in patients with muscle-Invasive bladder cancer (MIBC) (ChiCTR2500115561)
    P=N/A, N=20, Not yet recruiting, Tianjin Cancer Hospital Airport Hospita; Tianjin Cancer Hospital Airport Hospita
    New trial
    |
    carboplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    Prospective, Open-Label, Single-Center Clinical Study of Iparomlimab and Tuvonralimab Combined with AG Regimen plus SBRT versus Epalolitovorimab Combined with AG Regimen as First-Line Treatment for Unresectable Locally Advanced or Metastatic Pancreatic Cancer (ChiCTR2500115120)
    P=N/A, N=40, Not yet recruiting, The First Affiliated Hospital of University of science and technology of China; The First Affiliated Hospital of University of science and technology
    New trial
    |
    gemcitabine • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    A Single-Arm, Exploratory Study of QL1706 Combined with Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer (ChiCTR2500114856)
    P=N/A, N=30, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
    New trial
    |
    Qibeian (iparomlimab/tuvonralimab)
    3d
    A study on the efficacy and safety of iparomlimab and tuvonralimab (QL1706) in combination with gemcitabine and albumin-bound paclitaxel (GA) as first-Line therapy for advanced cholangiocarcinoma (ChiCTR2500114460)
    P=N/A, N=25, Not yet recruiting, Yunnan Cancer Hospital; Yunnan Cancer Hospital
    New trial
    |
    gemcitabine • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    3d
    Iparomlimab and Tuvonralimab combined with chemotherapy as second-line treatment for locally advanced or metastatic pancreatic cancer A prospective, open-label, single-arm clinical study (ChiCTR2500114040)
    P=N/A, N=29, Not yet recruiting, Harbin medical university cancer hospital; Harbin medical university cancer hospital
    New trial
    |
    5-fluorouracil • irinotecan • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    An Exploratory Study of Iparomlimab/Tuvonralimab (QL1706) Combined with Induction Chemotherapy and Radio(chemo)therapy for the Full-course Treatment of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (ChiCTR2500113996)
    P=N/A, N=50, Not yet recruiting, Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital
    New trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    Real-world study of Iparomlimab/Tuvonralimab-based therapy for hepatobiliary tumors (ChiCTR2500113841)
    P=N/A, N=30, Not yet recruiting, Nantong Tumor Hospital; Nantong Tumor Hospital
    New trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)